Matinas Biopharma (NYSE: MTNB) up 313% - the Candida drug actually works

Matinas Biopharma (NYSE: MTNB) stock jumped 313% yesterday then fell back 24%. MTNB stock raced ahead because their trial treatment seems to have actually cured a patient. This was not, though, as a part of a controlled and random testing regime so therefore we shouldn’t read too much into it. But this is also useful evidence that the company actually has something useful to be testing which is information of value in itself.

What’s done at Matinas: “Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company’s LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients.”

It’s that second drug there which has produced these results: “Matinas BioPharma (NYSE American: MTNB), announces complete clinical resolution of a patient’s recurrent hemorrhagic cystitis due to Candida krusei (C. krusei), a fluconazole inherited resistant fungal pathogen, following treatment with MAT2203, Matinas’ oral formulation of the potent antifungal amphotericin B. This patient was treated under Matinas’ Expanded Access/Compassionate Use Program”

MTNB

Matinas Biopharma stock price from Google Finance

As this wasn’t part of the controlled testing regime in some ways it doesn’t really count. On the other hand it is clear information even if not evidence of that court-level standard. The reason they’re able to test it in this manner is that there are no other treatments available - which bodes will if full FDA authorisation is eventually given.

Also worth noting that the varied Candidas are a hot topic at present. There are a number of drug resistant versions out there and little, so far, to cure them. T2 Biosystems, all the excitement there is over their new treatment for Candida Auris for example.

As so often happens science has got to the stage where new treatments are available and we get several developing similar such at the same time. These Candidas are different, yes, so are the treatments, but we’re seeing the exploration of several of them at the same time. The base level of science hsa reached the point where we can begin to address them that is.